AzTrials
AzTrials

Systemic Lupus Erythematosus (SLE)WHEELNCT06720584

Whole Health Empowerment for Endotypes of Lupus: Improving Quality of Life in SLE

A study testing Health coach-led, online support program for people living with lupus in people with Systemic Lupus Erythematosus (SLE), run by Duke University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

For people living with people living with systemic lupus erythematosus (SLE) the symptoms with the largest impact on their quality of life - fatigue, pain, and brain fog - are not always addressed in rheumatology clinic visits. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Systemic Lupus Erythematosus (SLE)
What is being tested?
Health coach-led, online support program for people living with lupus
Could I receive a placebo?
No, everyone receives an active treatment
How many people
36 participants
Where
1 siteUnited States
Study dates
7 Mar 2025to 31 Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • enrolled in the Duke Lupus Registry* for ≥1 year; (2) had ≥ 3 visits in the Duke Lupus Registry, (3) attended a Duke Lupus clinic visit in the last year, (4) meets Type 1 \& 2 SLE Activity criteria as defined below, (5) meets Persistent Type 2 SLE or Intermittent Type 2 SLE criteria as described below, (meets classification criteria for SLE (SLICC, ACR, or EULAR/ACR)), (7) female.
  • Active Type 1: SLEDAI ≥6, clinical SLEDAI ≥4, Type 1 PGA ≥1, or active lupus nephritis
  • Active Type 2: PSD: ≥8 or Type 2 PGA ≥1
  • Persistent Type 2 SLE: Active Type 2 SLE at 3 visits, Active Type 1 SLE at 0-2 visits
  • Intermittent Type 2 SLE: Active Type 2 SLE at 1-2 with Active Type 1 SLE at 1-3 visits
  • Participants will be stratified based on their Type 2 SLE activity in the prior 3 Duke Lupus Clinic visits as defined above.
  • Duke Lupus Registry participants must be age ≥18 years; disease duration of ≥1 year; ability to speak and read English; able to consent themselves

Who cannot join

  • significant cognitive impairment as determined by the treating rheumatologist; (2) untreated serious mental illness; (3) inability to provide informed consent; (4) participation in Aim 2 WHEEL curriculum development; (5) does not commit to attending sessions and using a tablet/computer. All participants will provide e-consent.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Duke University

    Durham, North Carolina, 27710

Other trials in United States

About this study

Official title: WHEEL: Improving Quality of Life in SLE by Stratified Personalized Health Planning

For people living with people living with systemic lupus erythematosus (SLE) the symptoms with the largest impact on their quality of life - fatigue, pain, and brain fog - are not always addressed in rheumatology clinic visits. To address the quality-of-life limitations, the investigators have created and will test the health coach-led, 8-session Whole Health Empowerment for Endotypes of Lupus (WHEEL) online support program. This program moves beyond traditional clinic visits and standard educational curricula to engage patients in creating their own health goals and therapeutic plans in a setting that emphasizes both the psychosocial and clinical factors contributing to disease. Participants will attend the virtual sessions, work with their health coach on two additional sessions, and complete surveys.

Read the detailed description

The investigators have created the WHEEL Program* (explained below) based on a previously developed Personalized Health Planning model, patient surveys, patient and provider focus groups feedback for WHEEL curricula and materials, and a User Testing of the WHEEL Program. The objective is to assess the feasibility of the WHEEL program, including its acceptability, demand, implementation, practicality, integration, and preliminary efficacy as an approach to improve quality of life in people with SLE. Our working hypothesis is that the WHEEL protocol will be feasible and acceptable to patients with SLE and demonstrate initial efficacy for improving quality of life. The investigators expect, however, that patients with Intermittent and Persistent Type 2 SLE* (see description below) will experience improvement in different domains of quality of life based on their initial deficits and the content of each program. At the completion of this proposal, the investigators will have a tested, feasible, and expandable protocol that the investigators will be prepared to test in larger SLE populations. This work represents a dramatic breakthrough for SLE self-management programs, tailoring the program to the specific SLE endotypes, providing essential group support, and empower patients with SLE to take control of their disease to improve their quality of life.

WHEEL Program Key Elements:

  1. Eight, virtual, bi-weekly group sessions, ~ 60-90 minutes per session
  2. Program facilitated by a certified health coach with clinical licensure and supported by a co-facilitator
  3. Themed group sessions focusing on understanding disease, medications and symptoms, motion/exercise, sleep/rest, nutrition, mindfulness/stress management, and personal goals.
  4. Curriculum comprised into a patient notebook with interactive and educational content, activities, and figures that mirror the information and activities that comprise the group sessions.
  5. Each group session includes interactive activities, health coaching, goal progress tracking, mindfulness-based practices, group discussion, social support, and empathy and empowerment between patients
  6. One-on-one consultation with health coach to develop a Personal Health Plan supported by shared patient-provider health assessments (i.e., Patient Health Self-Assessment and Provider Health Risk Assessment)
  7. Follow-up one-on-one consultation with the health coach to enhance engagement through motivational coaching based on patient-identified priorities and health goals.

Description of Type 1 and 2 SLE symptoms, Intermittent and Persistent Type 2 SLE:

A team of clinicians and investigators within the Duke Lupus Clinic developed a new approach to SLE care by creating the Type 1 \& 2 SLE Model. In this model, signs and symptoms of SLE are divided into two broad categories. Type 1 SLE symptoms consist of what is classically considered SLE activity and recorded in provider-reported measures of SLE activity, including synovitis, cutaneous lupus, nephritis, and other objective signs. Type 2 SLE symptoms include fatigue, myalgia, mood disturbance, and cognitive dysfunction. Duke researchers further refined the model and propose two endotypes of SLE: Intermittent Type 2 SLE (correlation between Type 1 \& 2 SLE symptoms, with both sets of symptoms worsening and improving around the same time) and Persistent Type 2 SLE (omnipresent Type 2 SLE symptoms that do not fluctuate when they have flares of Type 1 SLE).

Being tested
Health coach-led, online support program for people living with lupus
Keywords
systemic lupus erythematosus, SLE, Type 2 SLE, health coach, support program, mindfulness, fatigue, brain fog, pain
Medical subject headings
Lupus Erythematosus, Systemic, Fatigue, Mental Fatigue, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Health coach-led, online support program for people living with lupusBehavioural

    The health coach-led online support and education program for people living with lupus. It includes 8 group sessions and 2 individual sessions with the health coach to set individual goals. Each program group will include up to 10 participants.

    Program Session Structure (~60-75 minutes): educational component presented using a slide set, discussion questions interspersed, mindfulness activities, goal check-ins.

    Associated Materials: Notebook, expert videos available.

Study groups in NCT06720584
Study groupRoleWhat they receive
Group 1: Immediate TreatmentExperimentalGroup 1 participants receive the intervention first which is completing the 4-month program. They will receive an additional survey when Group 2 completes the intervention.
Receives: Behavioral: Health coach-led, online support program for people living with lupus
Group 2: Wait-List Control (Delayed Intervention)OtherGroup 2: Wait-List Control (Delayed Intervention) does not get the intervention while Group 1 is getting the intervention. Group 2 receives the intervention AFTER Group 1 has completed the intervention.
Receives: Behavioral: Health coach-led, online support program for people living with lupus

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Participant Satisfaction

    • Study-specific survey asking participants about their satisfaction on a scale from 0=completely unsatisfied to 10=completely satisfied

    Measured: Post-intervention (within four weeks of intervention ending)

  2. Intervention Adherence

    Total number of group sessions and health coach sessions attended.

    Measured: 10-months post-baseline

  3. Survey Completion

    Count the total number of surveys completed at 10 months post-baseline. Participants are to complete 2 surveys, LupusPRO and Whole Health Assessments pre-intervention, and 2 surveys, LupusPRO and Whole Health Assessments post-intervention.

    The range of completed surveys is 0-4 surveys, 0-100% complete. Completion of the entire survey is counted as completed.

    Measured: 10-months post-baseline

Secondary outcomes (2)
  1. Participant Accrual

    Number of participants consented to the study.

    Measured: Baseline

  2. Participant Attrition

    Number of consented participants who withdrew/were withdrawn from the program.

    Measured: 10-months post-baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Dec 2024
  2. Study start7 Mar 2025
  3. Primary completion31 Dec 2025
  4. Study completion31 Dec 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
Pilot randomized wait-list controlled trial
Masking
None (open label)
Enrolment
36 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06720584
Sponsor's protocol ID
Pro00111699
Other IDs
W81XWH-22-1-0611
Acronym
WHEEL
Status last verified
Jan 2026
First submitted
12 Nov 2024
Last updated
5 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Health coach-led, online support program for people living with lupus in people with Systemic Lupus Erythematosus (SLE), run by Duke University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Participant Satisfaction (time frame: Post-intervention (within four weeks of intervention ending)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in